Calliditas TherapeuticsCALT
Market Cap: $1.09B
About: Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
Employees: 222
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
70% more capital invested
Capital invested by funds: $18.9M [Q1] → $32.3M (+$13.3M) [Q2]
0.09% less ownership
Funds ownership: 1.47% [Q1] → 1.39% (-0.09%) [Q2]
5% less funds holding
Funds holding: 19 [Q1] → 18 (-1) [Q2]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
71% less call options, than puts
Call options by funds: $331K | Put options by funds: $1.13M
Research analyst outlook
We haven’t received any recent analyst ratings for CALT.
Financial journalist opinion
Based on 3 articles about CALT published over the past 30 days